Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_10656 is a synthetic small molecule belonging to the phenylbenzimidazole class of organic compounds. Its chemical formula is C18H20N4O2, and it has been studied primarily as a selective inhibitor of trypsin-like serine proteases, particularly targeting the S1 site of these enzymes. Structural studies have demonstrated its binding to trypsin 1, indicating its potential utility in modulating protease activity for research or therapeutic purposes[1][4][9]. There is no evidence that it has advanced into clinical development for any specific disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRA_10656.